DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
Q2 2022 13F-HR Holdings
Net value change ($000)
+375,435
(8.4%)
New positions
12
Sold out positions
12
Turnover %
11.4%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q1 2022
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| ImmunoGen, Inc. | 51,072 | 309.2% |
| GILD | 50,461 | 110.9% |
| DAWN | 42,169 | 203.7% |
| COGT | 41,018 | 342.1% |
| NBIX | 40,780 | 26.2% |
| Merus N.V. | 33,407 | 289.1% |
| Deciphera Pharmaceuticals, Inc. | 30,469 | 58.9% |
| HilleVax, Inc. | 28,614 | NEW |
| EOLS | 28,348 | 205.5% |
| GKOS | 25,850 | 121.0% |
Top Reduces (Value $000, Stocks/ETFs)
| CareMax, Inc. | -64,237 | -52.7% |
| ORGO | -42,736 | -66.3% |
| LUNG | -40,663 | -44.4% |
| IVERIC bio, Inc. | -32,173 | -39.1% |
| ATEC | -25,511 | -61.7% |
| Horizon Therapeutics Public Ltd Co | -23,958 | -49.0% |
| KURA | -22,862 | -32.2% |
| Mirati Therapeutics, Inc. | -22,199 | -100.0% |
| GDRX | -18,926 | -100.0% |
| NUVB | -18,816 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
101,970
(2.1% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|